Developing questions to assess and measure patients' perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
Clin Exp Med. 2024 Feb 14;24(1):36. doi: 10.1007/s10238-023-01261-4.ABSTRACTThis mixed method study developed multiple question types to understand and measure women's perceived benefit from adjuvant endocrine therapy. We hypothesis that patients do not understand this benefit and sought to develop the questions needed to test this hypothesis and obtain initial patient estimates. From 8/2022 to 3/2023, qualitative interviews focused on assessing and modifying 9 initial varied question types asking about the overall survival (OS) benefit from adjuvant endocrine therapy. Subsequent focus groups modified and selected the opti...
Source: Clinical Breast Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Bernard Tawfik Kendal Jacobson Ursa Brown-Glaberman Mikaela Kosich M Lee Van Horn Jacklyn Nemunaitis Zoneddy Dayao V Shane Pankratz Andrew L Sussman Dolores D Guest Source Type: research
The clinical impact of plasma estrogen receptor-1 mutation in patients with metastatic breast cancer: A meta-analysis
CONCLUSION: According to the findings of this meta-analysis, the assessment for plasma ESR1 mutations may provide prognostic and clinical guidance regarding subsequent endocrine therapy decisions for ER-positive, metastatic BC patients who had received prior therapy with AIs.PMID:38353504 | DOI:10.17219/acem/175816 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Xiaoli Zhang Ye Tian Dan Mo Wenli Chen Yi Ding Yanjiang Yang Xinning Li Source Type: research
Developing questions to assess and measure patients' perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
Clin Exp Med. 2024 Feb 14;24(1):36. doi: 10.1007/s10238-023-01261-4.ABSTRACTThis mixed method study developed multiple question types to understand and measure women's perceived benefit from adjuvant endocrine therapy. We hypothesis that patients do not understand this benefit and sought to develop the questions needed to test this hypothesis and obtain initial patient estimates. From 8/2022 to 3/2023, qualitative interviews focused on assessing and modifying 9 initial varied question types asking about the overall survival (OS) benefit from adjuvant endocrine therapy. Subsequent focus groups modified and selected the opti...
Source: Clinical Genitourinary Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Bernard Tawfik Kendal Jacobson Ursa Brown-Glaberman Mikaela Kosich M Lee Van Horn Jacklyn Nemunaitis Zoneddy Dayao V Shane Pankratz Andrew L Sussman Dolores D Guest Source Type: research
The clinical impact of plasma estrogen receptor-1 mutation in patients with metastatic breast cancer: A meta-analysis
CONCLUSION: According to the findings of this meta-analysis, the assessment for plasma ESR1 mutations may provide prognostic and clinical guidance regarding subsequent endocrine therapy decisions for ER-positive, metastatic BC patients who had received prior therapy with AIs.PMID:38353504 | DOI:10.17219/acem/175816 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Xiaoli Zhang Ye Tian Dan Mo Wenli Chen Yi Ding Yanjiang Yang Xinning Li Source Type: research
Developing questions to assess and measure patients ’ perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
AbstractThis mixed method study developed multiple question types to understand and measure women ’s perceived benefit from adjuvant endocrine therapy. We hypothesis that patients do not understand this benefit and sought to develop the questions needed to test this hypothesis and obtain initial patient estimates. From 8/2022 to 3/2023, qualitative interviews focused on assessing and modifying 9 initial varied question types asking about the overall survival (OS) benefit from adjuvant endocrine therapy. Subsequent focus groups modified and selected the optimal questions. Patients’ self-assessment of their OS benefit wa...
Source: Clinical and Experimental Medicine - February 14, 2024 Category: Research Source Type: research
Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
(Source: BMC Cancer)
Source: BMC Cancer - February 13, 2024 Category: Cancer & Oncology Authors: Xiewei Huang, Yushuai Yu, Shiping Luo, Wenfen Fu, Jie Zhang and Chuangui Song Tags: Correction Source Type: research
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
CONCLUSIONS: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.PMID:38344045 | PMC:PMC10853028 | DOI:10.1055/a-2238-3153 (Source: Geburtshilfe und Frauenheilkunde)
Source: Geburtshilfe und Frauenheilkunde - February 12, 2024 Category: OBGYN Authors: Carolin C Hack Nicolai Maass Bahriye Aktas Sherko K ümmel Christoph Thomssen Christopher Wolf Hans-Christian Kolberg Cosima Brucker Wolfgang Janni Peter Dall Andreas Schneeweiss Frederik Marme Matthias Ruebner Anna-Katharin Theuser Nadine M Hofmann Sybil Source Type: research
Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial
CONCLUSIONS: The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.PMID:38345755 | DOI:10.1158/1078-0432.CCR-23-2436 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 12, 2024 Category: Cancer & Oncology Authors: John M S Bartlett Keying Xu Jenna Wong Gregory Pond Yi Zhang Melanie Spears Ranelle Salunga Elizabeth Mallon Karen J Taylor Annette Hasenburg Christos Markopoulos Luc Dirix Cornelis J H van de Velde Daniel Rea Catherine A Schnabel Kai Treuner Jane Bayani Source Type: research
Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial
CONCLUSIONS: The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.PMID:38345755 | DOI:10.1158/1078-0432.CCR-23-2436 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: John M S Bartlett Keying Xu Jenna Wong Gregory Pond Yi Zhang Melanie Spears Ranelle Salunga Elizabeth Mallon Karen J Taylor Annette Hasenburg Christos Markopoulos Luc Dirix Cornelis J H van de Velde Daniel Rea Catherine A Schnabel Kai Treuner Jane Bayani Source Type: research
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
CONCLUSIONS: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.PMID:38344045 | PMC:PMC10853028 | DOI:10.1055/a-2238-3153 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Carolin C Hack Nicolai Maass Bahriye Aktas Sherko K ümmel Christoph Thomssen Christopher Wolf Hans-Christian Kolberg Cosima Brucker Wolfgang Janni Peter Dall Andreas Schneeweiss Frederik Marme Matthias Ruebner Anna-Katharin Theuser Nadine M Hofmann Sybil Source Type: research
Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial
CONCLUSIONS: The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.PMID:38345755 | DOI:10.1158/1078-0432.CCR-23-2436 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 12, 2024 Category: Cancer & Oncology Authors: John M S Bartlett Keying Xu Jenna Wong Gregory Pond Yi Zhang Melanie Spears Ranelle Salunga Elizabeth Mallon Karen J Taylor Annette Hasenburg Christos Markopoulos Luc Dirix Cornelis J H van de Velde Daniel Rea Catherine A Schnabel Kai Treuner Jane Bayani Source Type: research
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
CONCLUSIONS: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.PMID:38344045 | PMC:PMC10853028 | DOI:10.1055/a-2238-3153 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Carolin C Hack Nicolai Maass Bahriye Aktas Sherko K ümmel Christoph Thomssen Christopher Wolf Hans-Christian Kolberg Cosima Brucker Wolfgang Janni Peter Dall Andreas Schneeweiss Frederik Marme Matthias Ruebner Anna-Katharin Theuser Nadine M Hofmann Sybil Source Type: research
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
CONCLUSIONS: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.PMID:38344045 | PMC:PMC10853028 | DOI:10.1055/a-2238-3153 (Source: Geburtshilfe und Frauenheilkunde)
Source: Geburtshilfe und Frauenheilkunde - February 12, 2024 Category: OBGYN Authors: Carolin C Hack Nicolai Maass Bahriye Aktas Sherko K ümmel Christoph Thomssen Christopher Wolf Hans-Christian Kolberg Cosima Brucker Wolfgang Janni Peter Dall Andreas Schneeweiss Frederik Marme Matthias Ruebner Anna-Katharin Theuser Nadine M Hofmann Sybil Source Type: research
